GlassScriptPhysician profile
Nong Chrang
NPI 1043673379
$1,333.04
in general payments reported to CMS, 2019-2025
14 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $372 · 2024: $599 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $555.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $146.01 | 2023-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $110.34 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $80.61 | 2023-2024 | Injectafer |
| Amgen INC. | $64.54 | 2023-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $58.20 | 2023-2024 | Bexsero, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $56.58 | 2023 | Ajovy, Austedo Xr |
| Pfizer INC. | $50.37 | 2024 | |
| Merck Sharp & Dohme LLC | $45.77 | 2024 | M-M-R II, Gardasil, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.60 | 2023-2025 | Trulance, Xifaxan, Relistor |
| Lilly USA, LLC | $38.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $31.26 | 2024 | Rexulti |
| Exact Sciences Corporation | $27.89 | 2023 | Cologuard Collection Kit |
| Baxter Healthcare | $26.88 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nong Chrang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.